SCHEMBL27165201

SCHEMBL27165201

O=c1nc(C2CC(O)C(CO)O2)nc[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.41
DNMT1 P26358 1/20 0.41
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TK1 P04183 3/20 0.36
PNP P00491 2/20 0.34
ALOX12 P18054 1/20 0.34
ADRA1A P35348 1/20 0.34
GALR3 O60755 1/20 0.34
NR2F2 P24468 1/20 0.34
PIM1 P11309 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
CSNK2A3 Q8NEV1 1/20 0.33
TK2 O00142 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8663124 0.76 ADRB1 (0.38) ADRB1DNMT1LMNASMN1; SMN2TK1
SCHEMBL9751247 0.76 ADRB1 (0.38) ADRB1DNMT1LMNASMN1; SMN2TK1
SCHEMBL9634749 0.74 LMNA (0.37) ADRB1DNMT1LMNASMN1; SMN2TK1
SCHEMBL9633782 0.74 LMNA (0.37) ADRB1DNMT1LMNASMN1; SMN2TK1
SCHEMBL10533413 0.74 DPP4 (0.40) ADRB1DNMT1LMNASMN1; SMN2PNP
SCHEMBL7646510 0.74 PDPK1 (0.41) ADRB1DNMT1LMNASMN1; SMN2PNP
SCHEMBL1047109 0.74 ADRB1 (0.33) ADRB1DNMT1LMNASMN1; SMN2PNP
SCHEMBL29673050 0.74 TYRO3 (0.40) ADRB1DNMT1LMNASMN1; SMN2TK1
SCHEMBL10702398 0.73 PIM1 (0.39) ADRB1DNMT1LMNASMN1; SMN2PNP
SCHEMBL3227328 0.73 PIM1 (0.39) ADRB1DNMT1LMNASMN1; SMN2PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580635-A1 COMBINATION THERAPIES FOR TREATMENT OF T-CELL LYMPHOMAS WITH TOLINAPANT, CEDAZURIDINE AND DECITABINE Taiho Pharmaceutical Co., Ltd. (JP) 2025-07-09 EP disclosed
WO-2024047394-A1 COMBINATION THERAPIES FOR TREATMENT OF T-CELL LYMPHOMAS WITH TOLINAPANT, CEDAZURIDINE AND DECITABINE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-07 WO disclosed